Month: February 2018

Inflexxion to exhibit at the American Association for Treatment of Opioid Dependence conference

Inflexxion is exhibiting at the American Association for the Treatment of Opioid Dependence conference from March 10-14 at the New York Marriot Marquis in New York, NY. Visit us at booth #711 to learn more about our addiction treatment products, the ASI-MV product suite, as well as our opioid risk assessment, PainCAS. The American Association for the Treatment of… Read more »

Inflexxion to speak at the Abuse Deterrent Formulations Summit

Inflexxion’s Jody Green will be speaking at the Abuse Deterrent Formulations Summit on March 13 & 14 in Silver Springs, Maryland at the Sheraton Silver Springs Hotel. The following is an abstract of Dr. Green’s presentation titled “Measures of ADF Effectiveness: Alignment of Intended Impact and Postmarket Outcome Measures.” Abstract Jody L Green, PhD, CCRP Chief Scientific… Read more »

Your questions about the SOAPP-8 answered

What is the SOAPP-8? Broadly defined, the SOAPP-8 is a clinical tool used to determine a patient’s level of risk of misusing their opiate medication and the level of monitoring a patient on long-term opioid therapy may require. It was developed based on expert consensus regarding qualities likely to predict a patient’s risk of displaying… Read more »

Medication-assisted treatment: a solution or substitution?

Though thoroughly researched and validated as a highly effective means of treatment for those fighting opioid addiction, medication-assisted treatment, commonly abbreviated as MAT, faces opposition from the public, health professionals, and sometimes patients themselves. In May of 2017, Secretary of Health and Human Services Tom Price said about medication-assisted treatment, “if we’re just substituting one… Read more »